Eric Singhi, Thoracic Medical Oncologist at MD Anderson Cancer Center, shared on LinkedIn:
“BTGLung2026 kicks off with small cell lung cancer…
What’s known, and what may be changing?
- Tarlatamab is our preferred 2L option.
- ADCs are emerging.
- Will our 1L treatment for ES-SCLC change?
One of the most challenging problems in thoracic oncology? SCLC transformation.
It’s an area of tremendous unmet need, particularly for patients with young-onset lung cancer. Triparna Sen reviews the latest data and emerging directions at BTGLung2026.
DLL3-directed therapies have officially arrived in SCLC. The question is no longer IF to use them…but WHEN. Dr. Alissa Cooper reviews the evolving treatment landscape at BTGLung2026.
Paraneoplastic syndromes in SCLC: a rare ‘board exam’ topic, or truly something every practicing oncologist should recognize? Dr. Coral Olazagasti reviews the latest data at BTGLung2026.
Now we tackle gaps in EGFR+ lung cancer here at BTGLung2026
First take home point… not all EGFR ‘positive’ lung cancers are the same.
Top 5 gaps in EGFR+ lung cancer today?
- Who really needs combo therapy?
- How do we choose b/w frontline combos?
- Is TKI monotherapy still enough?
- Can we reduce toxicity w/o sacrificing efficacy?
- Should we treat earlier to improve long-term outcomes?
I’ve said this often… in lung cancer management, think chess, not checkers.
Dr. Sandip Patel agrees, and stresses this message here at BTGLung2026 for our patients w/ EGFR+ lung cancer.
5 biggest unanswered questions in early-stage EGFR lung cancer?
- Who needs chemotherapy?
- How long should we treat?
- Can ctDNA guide decisions?
- Who benefits from perioperative therapy?
- What’s the best strategy at recurrence?
Dr. Brendon Stiles kicks off day 2 of BTGLung2026.
‘Unresectable’ should be a multidisciplinary discussion…not a reflex.
As our systemic therapies improve, reassessment after induction may create opportunities that didn’t exist at diagnosis. Are we reevaluating enough?
CM77T shows us something important: biology doesn’t know whether a patient has single- or multistation N2 disease.
Those at the highest risk of micrometastatic disease may also have the most to gain from our best systemic therapy upfront.
Borderline resectable NSCLC – the path forward?
- Think biology > anatomy.
- Systemic therapy first.
- Always reassess resectability.
- Don’t label unresectable too early.
- Right patient. Right therapy. Right time.
Top 5 questions still shaping the role of RT in oligometastatic NSCLC:
- Who?
- When?
- Where?
- How much?
- Which biology?
Quick plug for our JAMA Oncology patient page on LCT in lung cancer.
Oligometastatic NSCLC – what would be your next step in management?
Management after neoadjuvant therapy in NSCLC?
Very timely review of the evolution of ROS1 directed TKIS happening here at BTGLung2026.
And now, HOT off the press as of THIS MORNING, FDA approval for zidesamtinib in patients who received a prior ROS1 TKI.”
Brain-Only Progression in ES-SCLC: When the Brain Progresses, the Systemic Backbone May Still Matter